Penile cancer
Drug research and approvals for penile cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 28 studies of penile cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.
- Recruiting worldwide: 28
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
- Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer TreatmentNCT07685249 · Not applicable · Duke University · starts Nov 1, 2026
- EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile…NCT07518979 · Phase 2 · Jiyan Liu · starts Jul 22, 2026
- A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile CancerNCT07497919 · Phase 2 · Fudan University · starts Sep 1, 2026
- QL1706 Plus Lenvatinib in Previously Treated Penile CancerNCT07384416 · Phase 2 · Sun Yat-sen University · starts Apr 10, 2026
- DEfeating PEnile CAncer-2NCT07378670 · Not applicable · University Hospital Tuebingen · starts Apr 10, 2026
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced…NCT07217171 · Phase 1 · EvolveImmune United, Inc · starts Nov 13, 2025
- DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for…NCT07110038 · Phase 2 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · starts Dec 16, 2025
- Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) as First-Line Treatment for EGFR-Positive Locally Advanced or…NCT07054307 · Phase 2 · Jiyan Liu · starts Feb 12, 2026
- PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)NCT06875258 · Phase 4 · The Netherlands Cancer Institute · starts Jan 15, 2024
Phase 2 12
- CisplatinDNA inhibitor
- IfosfamideDNA inhibitor
- PaclitaxelTubulin inhibitor
- CabazitaxelTubulin inhibitor
- DocetaxelTubulin inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- DacomitinibEpidermal growth factor receptor erbB1 inhibitor
- VinflunineTubulin inhibitor
- NiraparibPoly [ADP-ribose] polymerase 2 inhibitor
- NimotuzumabEpidermal growth factor receptor erbB1 inhibitor
- DostarlimabProgrammed cell death protein 1 antagonist
Phase 1 or earlier 4
- EntinostatHistone deacetylase inhibitor
- Bintrafusp alfaProgrammed cell death 1 ligand 1 binding agent
- Immunocytokine NHS-IL12
- Pexipepimut-s
How its trials ended
68 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 12 whose ending is known, 67% met their primary endpoint, 8% missed it and 25% stopped early.
- Ongoing3146%
- Completed, result not reported2131%
- Met its primary endpoint812%
- Status unknown46%
- Stopped: enrollment or feasibility34%
- Missed its primary endpoint11%
| Apr 19, 2018 | International penile advanced cancer trial - inpactCisplatin/ Ifosfamide/ Paclitaxel | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Ongoing |
| Jan 9, 2018 | A phase 2, multi-centre, open-label study of avelumab (MSB0010718C) in locally advanced or metastatic penile cancer patients unfit for platinum-based…MSB0010718C (avelumab) | Princess Margaret Cancer Centre | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA